Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. [electronic resource]
Producer: 20011214Description: 721-4 p. digitalISSN:- 0268-3369
- Antineoplastic Agents -- adverse effects
- Antineoplastic Agents, Alkylating -- therapeutic use
- Benzamides
- Bone Marrow Transplantation -- adverse effects
- Colitis -- chemically induced
- Combined Modality Therapy
- Enzyme Inhibitors -- adverse effects
- Female
- Graft Survival
- Graft vs Host Disease -- etiology
- Graft vs Leukemia Effect
- Hematopoietic Stem Cell Transplantation
- Humans
- Hydroxyurea -- therapeutic use
- Imatinib Mesylate
- Immunosuppression Therapy
- Interferon-alpha -- therapeutic use
- Leukemia, Myeloid, Accelerated Phase -- drug therapy
- Leukemia, Myeloid, Chronic-Phase -- drug therapy
- Lymphocyte Transfusion
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm, Residual
- Neutropenia -- chemically induced
- Piperazines -- adverse effects
- Pyrimidines -- adverse effects
- Remission Induction
- Salvage Therapy
- Transplantation Conditioning
- Transplantation, Homologous
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.